ATOSSA THERAPEUTICS, INC.
For the period ended May 23, 2024. Filed May 23, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 23, 2024 · Filed May 23, 2024
Use the contents to explore the available documents and sections.
Contents
Summary Compensation Table
The following table sets forth the compensation earned by our President and Chief Executive Officer and Senior Vice President of Finance and Accounting, and our two former Chief Financial Officers (together, the “2023 Named Executive Officers”) for fiscal year 2023 and, in the case of Dr. Quay and Mr. Guse, fiscal year 2022:
| Name and Position · Year · Salary · Bonus · OptionAwards (1) · Non-equityIncentive PlanCompensation (2) · All OtherCompensation (3) · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Steven C. Quay, M.D. Ph. D. | President and Chief | 2023 | $705,910 | $— | $1,143,927 | $469,783 | $36,600 | $2,356,220 | ||
| Executive Officer | 2022 | $705,910 | $— | $2,019,697 | $402,369 | $32,900 | $3,160,876 | |||
| Heather Rees, CPA (inactive) | Senior Vice President | 2023 | $331,585 | $— | $166,818 | $152,460 | $36,600 | $687,463 | ||
| Finance and Accounting | ||||||||||
| Kyle Guse | Former Chief Financial Officer, | 2023 | $248,358 | $— | $342,790 | $— | $580,483 | $1,171,631 | ||
| General Counsel and Secretary | 2022 | $466,658 | $— | $788,918 | $239,395 | $32,900 | $1,527,871 | |||
| Greg Weaver | Former Chief Financial Officer | 2023 | $197,756 | (4) | $43,493 | (5) | $2,116,394 | $— | $21,783 | $2,379,426 |
(1)
The value of the option awards has been computed in accordance with ASC 718. Assumptions used in the calculations for these amounts are included in the notes to our financial statements included in our Annual Report. The options vest quarterly over two years from the date of grant, except for 125,000 options with a grant date fair value of $66,169 that were granted to Mr. Weaver in connection with his service as a non-employee director prior to commencing service as Chief Financial Officer, which options were scheduled to vest quarterly over one year from the date of grant, and 2,600,000 options with a grant date fair value of $2,050,225 that were granted to Mr. Weaver in connection with his appointment as Chief Financial Officer, which options were scheduled to vest 25% on the one-year anniversary of the date of grant with the remainder scheduled to vest in equal quarterly installments over the following three years. In connection with his termination of service as Chief Financial Officer and a member of the Board, however, all of Mr. Weaver’s unvested options were terminated.
(2)
Amounts represent the annual performance bonus.
(3)
Amounts represent the 401(k) match made by the Company on behalf of the Named Executive Officer and reimbursements under our wellness program. For Mr. Guse the amount also includes a $553,533 severance payment.
(4)
Includes $33,333 paid to Mr. Weaver in connection with his service as a non-employee director prior to becoming Chief Financial Officer.
(5)
Mr. Weaver received a sign on bonus of $125,000, but upon his resignation from the Company, he was required to return $81,507 to the Company per his employment agreement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.